Cholic Acid Reprograms RORγt + Th17 Cells into IL‐10‐Producing T Cells to Limit Experimental Colitis
European Journal of Immunology · 2026-10 · 56 (10)
DOI: 10.1002/eji.70301 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, online erschienen am 26.10.2026. Verfasst von Rajdeep Dalal und 17 weiteren Autor:innen. Beteiligte Einrichtung: Centre For Immunobiology and Immunotherapy, Translational Health Science and Technology Institute, NCR-Biotech Science Cluster, Faridabad, India. Hauptthemen laut MEDLINE: Interleukin-10, Th17 Cells, Nuclear Receptor Subfamily 1, Group F, Member 3, Cholic Acid. Die Arbeit nennt 41 Literaturangaben. Gefördert von: National Bioscience Award, DBT, India.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) is a relapsing‐remitting inflammatory disorder of the gastrointestinal tract driven by dysregulated T helper (Th)‐cell responses, gut microbiota imbalance, and altered bile acid metabolism. While cholic acid (CA), a primary bile acid, is immunotoxic at high concentrations, its immunomodulatory role at physiological levels remains unclear. Here, we evaluate the therapeutic potential of CA in an experimental colitis model. Administration of biologically tolerable CA significantly reduced disease activity, preserved colon length, and alleviated histological inflammation. Mechanistically, CA downregulated RORγt levels and promoted Th cell plasticity toward IL‐10‐producing phenotypes, resulting in diminished production of IFN‐γ and IL‐17. Dietary depletion of primary bile acid precursors and IL‐10 neutralization confirmed IL‐10‐dependent immunoregulation as a key mechanism. Additionally, synthetic derivatives of CA, similar to CA, attenuated DSS‐induced colitis by selectively expanding IL‐10‐producing Th cells. Collectively, these findings highlight CA and its synthetic derivatives as immunomodulatory candidates for the therapy of ulcerative colitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre For Immunobiology and Immunotherapy, Translational Health Science and Technology Institute, NCR-Biotech Science Cluster, Faridabad, India.
- Department of Chemistry and Centre for Advanced Studies in Chemistry, Panjab University, Chandigarh, India.
- Centre For Drug Discovery (CDD), Translational Health Science and Technology Institute, NCR-Biotech Science Cluster, Faridabad, India.
- Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, India.
ORCID-Profile: Rajdeep Dalal, Srikanth Sadhu, Akshay Binayke, Yashwant Kumar, Shailendra Asthana, Vineet Ahuja, Deepak Bhalchandra Salunke, Amit Awasthi
Förderung
- National Bioscience Award, DBT, India
Zitieren
APA
Dalal, R., Sadhu, S., Singla, P., Madan, U., Binayke, A., Suri, C., Goswami, S., Goswami, S., Tripathy, M. R., Kamboj, A., Rao, N., Kumar, Y., Rizvi, Z. A., Rathore, D. K., Asthana, S., Ahuja, V., Salunke, D. B., & Awasthi, A. (2026). Cholic Acid Reprograms RORγt + Th17 Cells into IL‐10‐Producing T Cells to Limit Experimental Colitis. European Journal of Immunology, 56(10). https://doi.org/10.1002/eji.70301
Vancouver
Dalal R, Sadhu S, Singla P, Madan U, Binayke A, Suri C, et al. Cholic Acid Reprograms RORγt + Th17 Cells into IL‐10‐Producing T Cells to Limit Experimental Colitis. European Journal of Immunology. 2026;56(10). doi:10.1002/eji.70301
BibTeX
@article{Dalal2026,
author = {Dalal, Rajdeep and Sadhu, Srikanth and Singla, Poonam and Madan, Upasna and Binayke, Akshay and Suri, Charu and Goswami, Sucheta and Goswami, Sandeep and Tripathy, Manas Ranjan and Kamboj, Aarzoo and Rao, Nagender and Kumar, Yashwant and Rizvi, Zaigham Abbas and Rathore, Deepak Kumar and Asthana, Shailendra and Ahuja, Vineet and Salunke, Deepak Bhalchandra and Awasthi, Amit},
title = {Cholic Acid Reprograms RORγt + Th17 Cells into IL‐10‐Producing T Cells to Limit Experimental Colitis},
journal = {European Journal of Immunology},
year = {2026},
volume = {56},
number = {10},
doi = {10.1002/eji.70301}
}
EUVIMED